Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells

Cancer Genomics and Proteomics

Volumn 6, Issue 2, 2009, Pages 101-108

  Bokobza, Sivan M ^a   Ye, Lin ^a   Kynaston, Howard E ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

BMPR IB; Bone morphogenetic protein; Cell proliferation and breast cancer; Prognosis

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 1B;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; TRANSGENE; TUMOR DIFFERENTIATION;

EID: 65749107319     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Ward SE, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58(2): 71-96, 2008.
2. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2): 6243s-6249s, 2006.
3. Koli KM and Arteaga CL: Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res 57(5): 970-977, 1997.
4. Chang CF, Westbrook R, Ma J and Cao D: Transforming growth factor-beta signaling in breast cancer. Front Biosci 12: 4393-4401, 2007.
5. Urist MR: Bone: formation by autoinduction. Science 150(698): 893-899, 1965.
6. Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors 22(4): 233-241, 2004.
7. Ye L, Lewis-Russell JM, Kyanaston HG and Jiang WG: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 22(10): 1129-1147, 2007.
8. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, Ogata E, Ehata S, Miyazono K and Imamura T: Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27(49): 6322-6333, 2008.
9. Alarmo EL, Korhonen T, Kuukasjarvi T, Huhtala H, Holli K and Kallioniemi A: A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 103(2): 239-246, 2007.
10. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clezardin P, Papapoulos SE, Cecchini MG, Lowik CW and van der Pluijm G: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67(18): 8742-8751, 2007.
11. Pouliot F and Labrie C: Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 172(1): 187-198, 2002.
12. Arnold SF, Tims E and McGrath BE: Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine 11(12): 1031-1037, 1999.
13. Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6): 685-700, 2003.
14. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI and Knaus P: The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277(7): 5330-5338, 2002.
15. Nohe A, Keating E, Knaus P and Petersen NO: Signal transduction of bone morphogenetic protein receptors. Cell Signal 16(3): 291-299, 2004.
16. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G and Vogelstein B: Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28(2): 184-187, 2001.
17. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK and Morton RA: Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60(11): 2840-2844, 2000.
18. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ and Morton RA: Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23(46): 7651-7659, 2004.
19. Pouliot F, Blais A and Labrie C: Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 63(2): 277-281, 2003.
20. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH and Buerger H: First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 206(3): 366-376, 2005.
21. Hanavadi S, Martin TA, Watkins G, Mansel RE and Jiang WG: The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast Cancer. Ann Surg Oncol 14(7): 2159-2166, 2007.
22. Davies SR, Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol 7(4): 327-338, 2008.
23. Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 6(10): 1594-606, 2008.
24. Gobbi H, Dupont WD, Simpson JF, Plummer WD Jr, Schuyler PA, Olson SJ, Arteaga CL and Page DL: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 91(24): 2096-2101, 1999.
25. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD Jr and Page DL: Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas. Histopathology 36(2): 168-177, 2000.
26. Rosman DS, Phukan S, Huang CC and Pasche B: TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 68(5): 1319-1328, 2008.
27. Takahashi M, Otsuka F, Miyoshi T, Otani H, Goto J, Yamashita M, Ogura T, Makino H and Doihara H: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol 199(3): 445-455, 2008.
28. Mery L, Lefevre A, Benchaib M, Demirci B, Salle B, Guerin JF and Lornage J: Follicular growth in vitro: detection of growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) during in vitro culture of ovine cortical slices. Mol Reprod Dev 74(6): 767-774, 2007.
29. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR and Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112(7): 1116-1124, 2003.
30. Kawabata M, Imamura T and Miyazono K: Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9(1): 49-61, 1998.